Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).
Michèle Beau-Faller, MD, PhD, of the Hôpital de Hautepierre & Institut Régional du Cancer, discusses study results on ultrasensitive detection of EGFR T790M mutation by droplet digital PCR in TKI naïve non–small cell lung cancer harboring EGFR mutation (Abstract 85PD).
Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups (Abstract LBA5).
Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.
Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolumab or ipilimumab alone (Abstract 1213O).
Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage III ovarian cancer.
